{
    "2018-02-01": [
        [
            {
                "time": "2018-02-01",
                "original_text": "复星医药：第七届董事会第五十二次会议(临时会议)决议公告",
                "features": {
                    "keywords": [
                        "复星医药",
                        "董事会",
                        "决议公告"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "智通港股公告精选︱2月1日",
                "features": {
                    "keywords": [
                        "智通港股",
                        "公告精选",
                        "2月1日"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "港股"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "港股复盘：短线忧虑情绪上升 恒指2月开门下跌",
                "features": {
                    "keywords": [
                        "港股复盘",
                        "短线忧虑",
                        "恒指",
                        "2月开门下跌"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "港股"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "[强于大市评级]生物医药行业动态跟踪报告：第二十六批拟纳入优先审评程序重点品种分析",
                "features": {
                    "keywords": [
                        "强于大市评级",
                        "生物医药",
                        "优先审评",
                        "重点品种分析"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "复星医药3款创新药获批临床 利妥昔单抗注射液有望成为国内首个生物类似药",
                "features": {
                    "keywords": [
                        "复星医药",
                        "创新药",
                        "利妥昔单抗",
                        "生物类似药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "[强烈推荐评级]复星医药(600196)事项点评：CD20靶点利妥昔单抗类似药纳入优先审评 上市步伐加快",
                "features": {
                    "keywords": [
                        "强烈推荐评级",
                        "复星医药",
                        "CD20靶点",
                        "利妥昔单抗",
                        "优先审评",
                        "上市步伐加快"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "中泰证券2月重点推荐标的",
                "features": {
                    "keywords": [
                        "中泰证券",
                        "2月重点推荐",
                        "标的"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "证券"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "[INCREASE评级] CHUANCAI RESEARCH 2018 STRATEGY REPORT：2018 CHINA EQUITY MARKET PHARMACEUTICAL OUTLOOK",
                "features": {
                    "keywords": [
                        "INCREASE评级",
                        "CHUANCAI RESEARCH",
                        "2018策略报告",
                        "医药展望"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "复星集团：全球布局投资保险科技",
                "features": {
                    "keywords": [
                        "复星集团",
                        "全球布局",
                        "投资",
                        "保险科技"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "保险科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}